Why do I choose the Spiromax® inhaler? Review article

Article Sidebar

PDF (Język Polski)


Published: Jun 30, 2021
DOI: https://doi.org/10.24292/01.AP.173300621
Keywords:
dry powder inhalers, Spiromax® inhaler, budesonide, formoterol, MART therapy, asthma

Main Article Content

Andrzej Emeryk
Klinika Chorób Płuc i Reumatologii Dziecięcej, Uniwersytet Medyczny w Lublinie
http://orcid.org/0000-0003-1853-8696

Abstract

The most important features of the Spiromax® dry powder inhaler are presented. Spiromax® is the most modern device, classified as third generation dry powder inhalers. It is characterized by a low minimum inspiratory flow, emitting a constant dose of the drug, regardless of the size of inspiratory flows generated by the patient. It produces high quality aerosol cloud with low MMAD and high FPF. DuoResp Spiromax® can be used in modern asthma therapy using the MART method.

Downloads

Download data is not yet available.

Article Details

How to Cite
Emeryk , A. (2021). Why do I choose the Spiromax® inhaler?. Alergoprofil, 17(3), 47-49. https://doi.org/10.24292/01.AP.173300621
Issue
Vol 17 No 3 (2021)
Section
THERAPY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Sosnowski TR. Aerozole wziewne i inhalatory. 2nd suppl ed. Politechnika Warszawska, Wydział Inżynierii Chemicznej i Procesowej, Warszawa 2012: 125-52.
2. Emeryk A, Pirożyński M, Sosnowski TR et al. Leksykon nebulizacyjny. Najczęściej spotykane i przydatne w praktyce pojęcia dotyczące nebulizacji. 1st ed. Lublin-Warszawa-Sieradz 2018: 1-22.
3. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. ViaMedica, Gdańsk 2021: 1-33.
4. Rönmark P, Jagorstrand B, Safioti G. Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler- naïve adult volunteers. Eur Clin Respir J. 2018; 5(1): 1529536.
5. Bosnic-Anticevich S, Callan C, Chrystyn H et al. Inhaler technique mastery and maintenance in healthcare professionals trained on different device. J Asthma. 2018; 55(1): 79-88.
6. Janson Ch, Lööf T, Telg G et al. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med. 2016; 26: 16053.
7. Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder (access: 10.06.2019).
8. Lewis A, Torvinen S, Dekhuijzen PNR et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017; 129: 179-88.
9. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005; 50(9): 1209-27.
10. Canonica GW, Arp J, Keegstra JR et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J Aerosol Med Pulm Drug Deliv. 2015; 28(5): 309-19.
11. ChPL. DuoResp Spiromax (access: 25.05.2021).
12. Lavorini F, Janson Ch, Braido F et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019; 13: 1753466619884532.
13. Chrystyn H, Safioti H, Keegstra JR et al. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. Inter J Pharma. 2015; 491: 268-76.
14. (access: 15.05.2021).
15. 2021 GINA Report, Global Strategy for Asthma Management and Prevention (2021 update) (access: 25.05.2021).
16. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020; 146(6): 1217-70.
17. ProAir RespiClick. Pediatric Postmarketing Pharmacovigilance Review (access: 24.05.2021).
18. Boer AH, Hagedoorn P, Hoppentocht M et al. Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017; 14(4): 499-512.